PRKCA and neoplasm: We found that PKCα or PKCδ knockdown significantly decreased LNCaP-NE survival in vitro and that in vivo treatment with enzastaurin, a powerful pan-PKC inhibitor, of castrated mice injected with LNCaP tumour cells resulted in a significant reduction of tumour growth.